Frekil

Frekil addresses the critical challenge of efficiently understanding real-world drug performance. The traditional process of analyzing drug effectiveness can take months, leading to delayed safety insights, prolonged approval timelines, and ultimately, impacting patient outcomes. Frekil dramatically accelerates this process, transforming months into minutes while maintaining full auditability and regulatory compliance.

By automatically generating real-world evidence (RWE) from electronic health records (EHR) and claims data, Frekil functions as an AI-powered biostatistician. The system possesses a deep understanding of medical ontologies and statistical methodologies, enabling it to autonomously execute intricate analyses.

Frekil empowers pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and clinical researchers to conduct RWE studies with unprecedented speed, achieving a 100x acceleration. The platform facilitates the creation of publication-ready retrospective studies and comprehensive evidence packages suitable for submission to regulatory bodies like the FDA and EMA, all with transparent data lineage and rapid turnaround times.